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Abstract
AIM: To compare 2-deoxy-2-(18F)fluoro-D-glucose(18F-
FDG) and 18F-sodium (18F-NaF) positron emission 
tomography/computed tomography (PET/CT) accuracy 
in breast cancer patients with clinically/radiologically 
suspected or known bone metastases.
METHODS: A total of 45 consecutive patients with 
breast cancer and the presence or clinical/biochemical 
or radiological suspicion of bone metastatic disease 
underwent 18F-FDG and 18F-fluoride PET/CT. Imaging 
results were compared with histopathology when 
available, or clinical and radiological follow-up of at least 
1 year. For each technique we calculated: Sensitivity 
(Se), specificity (Sp), overall accuracy, positive and 
negative predictive values, error rate, and Youden’s index. 
McNemar’s χ 2 test was used to test the difference in 
sensitivity and specificity between the two diagnostic 
methods. All analyses were computed on a patient 
basis, and then on a lesion basis, with consideration 
ofthe density of independent lesions on the co-
registered CT (sclerotic, lytic, mixed, no-lesions) and the 
divergent site of disease (skull, spine, ribs, extremities, 
pelvis). The impact of adding 18F-NaF PET/CT to the 
work-up of patients was also measured in terms of 
change in their management due to 18F-NaF PET/CT 
findings. 
RESULTS: The two imaging methods of 18F-FDG and 
18F-fluoride PET/CT were significantly different at the 
patient-based analysis: Accuracy was 86.7% and 
84.4%, respectively (McNemar’s χ 2 = 6.23, df = 1, P  
= 0.01). Overall, 244 bone lesions were detected in 
our analysis. The overall accuracy of the two methods 
was significantly different at lesion-based analysis 
(McNemar’s χ 2 = 93.4, df = 1, P  < 0.0001). In the 
lesion density-based and site-based analysis, 18F-FDG 
PET/CT provided more accurate results in the detection 
of CT-negative metastasis (P  < 0.002) and vertebral 
localizations (P  < 0.002); 18F-NaF PET/CT was more 
accurate in detecting sclerotic (P  < 0.005) and rib 
lesions (P  < 0.04). 18F-NaF PET/CT led to a change 
of management in 3 of the 45 patients (6.6%) by 
revealing findings that were not detected at 18F-FDG 
PET/CT. 
CONCLUSION: 18F-FDG PET/CT is a reliable imaging 
tool in the detection of bone metastasis in most cases, 
with a diagnostic accuracy that is slightly, but signi-
ficantly, superior to that of 18F-NaF PET/CT in the 
general population of breast cancer patients. However, 
the extremely high sensitivity of 18F-fluoride PET/CT 
can exploit its diagnostic potential in specific clinical 
settings (i.e. , small CT-evident sclerotic lesions, high 
clinical suspicious of relapse, and negative 18F-FDG PET 
and conventional imaging).
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Core tip: 18F-fluorodeoxyglucose (18F-FDG) and 18F-sodium 
positron (18F-NaF) positron emission tomography/
computed tomography (PET/CT) is undoubtedly an 
accurate and validated imaging tool in the general 
population of breast cancer patients for the detection of 
bone metastasis in most cases. However, thanks to its 
extremely high sensitivity, 18F-NaF PET/CT could have 
an adjunctive value in selected patients, significantly 
impacting their management (i.e. , small CT-evident 
sclerotic lesions, high clinical suspicious of relapse, and 
negative 18F-FDG PET and conventional imaging). This 
sensitivity might be particularly relevant for patients who 
are candidates for surgery or radiotherapy.
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INTRODUCTION
Breast cancer is the most prevalent form of cancer in 
women of Western countries[1-3], with the skeleton being 
the most common site of distant metastases. Presence, 
distribution, and type of bone localizations have relevant 
prognostic implications[4,5]. In particular, with the grow-
ing availability of new therapeutic strategies which could 
potentially improve survival, the early detection of bone 
metastases has gained pivotal importance[6,7].
Conventional bone scintigraphy (BS) remains the 
most suitable technique for whole-body screening of 
bone metastasis due to its low cost and high availability. 
However, BS has several important limitations, and 
so additional imaging procedures are often necessary 
to determine the real significance of scintigraphic 
abnormalities[8].
During the last decade, positron emission tomography 
(PET) has evolved from a research tool to an established 
imaging modality for the staging of different types of 
malignant tumors, owing to its better spatial resolution 
and superior image quality with respect to conventional 
single-photon imaging. Among PET tracers, glucose 
analogue 2-deoxy-2-(18F)fluoro-D-glucose (18F-FDG) has 
become the most widely used in clinical routine, resulting 
in a major impact on the practice of oncology[9]. In breast 
cancer patients, 18F-FDG-PET enables the detection 
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of neoplastic lesions on the basis of their increased 
glucose metabolism, potentially allowing for an accurate 
assessment of local disease, lymph nodes, and visceral 
metastases in a single imaging study. Furthermore, by 
directly reflecting tumor cell viability in bone metastases, 
this technique can potentially be used for therapy 
response assessments. In fact, changes in 18F-FDG 
activity after therapy may reflect an early response to 
therapy that could be potentially prognostic[10].
Characterization of bone metastases is also possible 
with 18F-sodium fluoride (18F-NaF), which reflects the 
increased regional blood flow and osteoblastic bone 
reaction[8]. Specifically, greater activity of remodeling 
and bone turnover determines greater blood flow and 
exchange surface for 18F-fluoride ion absorption and 
subsequent irreversible incorporation into the bone 
matrix as fluorapatite[11-13].
Both PET tracers have shown a better diagnostic 
value compared to BS in detecting bone metastases 
in patients with breast cancer and several other malig-
nancies[14-20]. Conversely, very limited and controversial 
information exists in comparing the diagnostic accuracy 
of 18F-FDG and 18F-NaF PET[19,21,22]. The different uptake 
mechanisms of these two tracers might be comple-
mentary in the context of evaluating lytic and sclerotic 
lesions, which can both coexist in bone localizations of 
breast cancer patients[23].
Furthermore, it has been suggested[24] that anato-
mical localization of the lesions could also influence the 
accuracy of each technique; this finding is likely to be 
related to the morphology of bone metastasis. In fact, 
the involvement of different skeletal segments could 
determine different degrees of osteoblastic reaction[25,26]. 
At the time of writing, controversial results have been 
reported about the accuracy of these two tracers in 
breast cancer patients[19,21,22], with some authors even 
proposing their combined use[27,28]. In particular, 18F-FDG 
PET/computed tomography (CT) can provide information 
about the presence/absence of disease in the skeleton, 
as well as in non-skeletal districts. In this context, it not 
been clearly investigated whether 18F-NaF PET/CT can 
provide incremental information for the management of 
breast cancer patients that have already been evaluated 
by means of 18F-FDG PET/CT.
The current study aims to evaluate the role of the 
two imaging modalities in the restaging of breast cancer 
patients with clinically/radiologically suspected or known 
metastatic bone lesions. In particular, we planned to 
verify whether the accuracy of the two imaging methods 
could be influenced by lesion density and location. 
MATERIALS AND METHODS
Patient population
Between January 2010 and June 2012, 45 breast 
cancer patients were referred to our institutions for the 
execution of both 18F-NaF and 18F-FDG PET/CT for the 
restaging of clinically/radiologicallysuspected or proven 
metastatic bone lesions. All study participants, or their 
legal guardians, provided informed written consent prior 
to study enrollment, and practices were performed in 
accordance with the ethical standards laid down in the 
Declaration of Helsinki. We included only patients who 
performed the two PET scans within 1 mo and did not 
received chemotherapy or radiotherapy between the two 
examinations. By contrast, chemotherapy administration 
in the month before the two PET/CT exams was not an 
exclusion criterion. Patient characteristics are listed in 
Table 1.
PET/CT protocols
Image acquisition was performed according to standard 
procedures and international guidelines[29,30].
Patients were submitted to 18F-NaF PET/CT using 
two 16 slices PET/CT hybrid systems: (1) Biograph 
16 (Siemens Medical Solutions, Knoxville TN, United 
States); and (2) Discovery LS (GE Medical Systems, 
Milwaukee, WI, United States) according to the standard 
procedure as previously detailed[31].
Image interpretation
Each 18F-FDG-PET/CT and 18F-NaF-PET/CT scan were 
independently evaluated by two nuclear medicine 
physicians aware of the patient’s clinical history but 
blinded to the results of the other PET/CT scan and that 
of other cross-sectional morphological imaging modalities 
[magnetic resonance imaging (MRI)/CT]. In cases of 
disagreement,a consensus obtained among readers 
was used for the final decision. For both 18F-NaF and 
18F-FDG PET/CT, scans were interpreted as negative 
for bone lesions when no pathologic tracer uptake 
was present within the skeleton. In cases of increased 
uptake within the joints, the exam was also considered 
negative. Similarly, for both 18F-NaF and 18F-FDG, avid 
lesions were diagnosed as benign when degenerative 
changes or fractures were detected on non-diagnostic CT. 
Conversely, the presence of focal tracer uptake associated 
with suspicious or indeterminate morphological changes 
on non-diagnostic CT were considered as positive. 
Similarly, for both 18F-NaF and 18F-FDG, high and focal 
uptake in the absence of lesions on the non-diagnostic 
CT was considered likely to be “micro-scleroses”, and 
thus classified as positive/malignant. 
For each lesion, density on the co-registered CT was 
recorded and lesions were divided into four groups:
Sclerotic, lytic, mixed, and no-lesions. Similarly, lesion 
localizations were also recorded to assess the impact 
of the divergent disease sites (skull, spine, ribs, extre-
mities, and pelvis).
Standard references
Since a bone biopsy of all lesions for histology was not 
considered appropriate for obvious ethical reasons, the 
radiological and clinical follow-up at 12 mo served as 
the standard of reference for the final evaluation of the 
results as true-positive, true-negative, false-positive, 
and false-negative. Follow-up information included 
physical examination, laboratory tests, tumor markers, 
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The two imaging methods were significantly diffe-
rent in the patient-based analysis, with anaccuracy of 
86.7% and 84.4%, respectively (McNemar’s χ 2 = 6.23, 
df = 1, P = 0.01.). See Table 2 for details on sensitivity, 
specificity, and predictive values of the two PET/CT 
modalities.
Overall lesion-based analysis
Overall, 244 bone lesions were detected in our analysis. 
The overall accuracy of the two methods was significantly 
different in the lesion-based analysis (McNemar’s χ 2 
= 93.4, df = 1, P < 0.0001). 18F-NaF showed high 
sensitivity (90.5%), but a very low specificity (17.5%). 
By contrast, although 18F-FDG PET/CT showed a lower 
sensitivity (66%), it was characterized by a significantly 
higher specificity (96.2%).
Lesion density- and site-based analysis
Significant differences were highlighted in the lesion 
density- and site- based analysis, as 18F-FDG PET/CT 
was more accurate in the detection of CT-negative meta-
stasis (P < 0.002),vertebral localizations (P < 0.002), 
and sclerotic (P < 0.005) and rib lesions (P < 0.04). 
No significant differences were highlighted with respect 
to accuracy in evaluating lytic and mixed lesions, or in 
lesions localized in the skull, distal extremities or pelvis. 
See Table 3 for details on sensitivity, specificity, and 
accuracy. Figures 1-3 show representative examples of 
the different performance of the two imaging modalities.
Impact on patient management
Findings that were found only in 18F-NaF PET/CT imag-
ing led to a change of management for 3 of the 45 
patients (6.6%). In particular, two patients underwent 
chemotherapy rather than targeted radiotherapy due to 
the detection of further skeletal lesions. One patient was 
excluded from surgical treatment of lung metastasis 
due to the presence of bone involvement.
DISCUSSION
In this study, we aimed to elucidate the role of 18F-FDG 
and 18F-NaF PET/CT in restaging breast cancer patients 
and other independent imaging studies (CT, MRI, 
18F-FDG PET/CT, X-ray studies, and bone scans).
Statistical analysis
For statistical analysis we used the “R” software pro-
gram[32] and DiagnosisMed software package[33]. We 
compared 18F-NaF PET/CT and 18F-FDG PET/CT results 
through patient-, lesion density-, and site-based analyses.
Cochran Q test followed by multiple comparisons 
using McNemar’s test with continuity correction and 
Bonferroni adjustment were used in order to assess 
differences among imaging modalities. P values less 
than 0.05 were considered statistically significant. The 
impact of adding 18F-NaF PET/CT to the work-up of 
patients was also measured in terms of changes to their 
management due to findings related to this functional 
imaging. 
The statistical methods of this study were reviewed 
by a biomedical statistician.
RESULTS
Overall diagnostic accuracy and patient-based analysis
Sixteen patients were negative and 16 patients were 
positive at both imaging modalities. Eleven and two 
patients were positive only ata single tracer (18F-FDG 
and 18F-NaF, respectively). Histology was used as 
standard references in two patients (specifically in 
one patient who was true positive for bone marrow 
involvement at 18F-FDG PET and in one patient who was 
true positive for the presence of an osteosclerotic lesion 
in the ribs detected by 18F-NaF only).
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Table 1  Patient characteristics (n  = 45)
Demography
Age (yr) 61 ± 10
Stage at diagnosis
   Ⅰ    5
   Ⅱ 21
   Ⅲ 14
   Ⅳ   5
Histology
   Ductal 35
   Lobular   8
   Other   2
Tumor receptor (+/-/unknown)
   Estrogen receptor 39/2/4
   PgR 29/11/5
   c-erb B2 14/24/7
Site of metastatic disease other than bone
   Lung 27%
   Liver 20%
   Lymph nodes 30%
Systemic therapy
   First-line 81%
   Second-line 62%
   Third-line 36%
   Bisphosphonates 22%
Follow-up (mean 28 mo range 22-39)
   Patients with disease progression 58%
   Patients dead from disease 30%
Table 2  Patient-based analysis: Performance comparisons 
between 2-deoxy-2-(18F)fluoro-D-glucose and 18F-sodium 
positron emission tomography/computed tomography
18F-FDG 18F-NaF
Sensitivity (%)    75.00 (55.10-88.00)   91.67 (74.15-97.68)
Specificity (%) 99.00 (84.54-100)   76.19 (54.91-89.37)
Positive predictive value (%) 99.00 (82.41-100) 81.48 (63.3 91.82)
Negative predictive value (%)    77.78 (59.24-89.39) 88.89 (67.2-96.90)
Error rate (%)  13.33 (6.26-26.18) 15.56 (7.75-28.78)
Accuracy (%)    86.67 (73.82-93.74)   84.44 (71.22-92.25)
Youden's index  0.75 (0.75-0.74) 0.6786 (0.68-0.6718)
Estimated parameters corresponding to each technique are presented with 
95%CI between square brackets. 18F-FDG: 2-deoxy-2-(18F)fluoro-D-glucose; 
18F-NaF: 18F-sodium.
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with bone lesions by means of patient-, density-, and 
site-based analyses.
Slight, but significant, differences were highlighted 
between 18F-FDG and 18F-NaF in the patient-based 
analysis, with the former showing higher specificity and 
the latter being characterized by higher sensitivity. These 
differences were more markedly evident at the lesion-
based analysis, where 18F-FDG showed higher accuracy 
for detecting CT-negative (likely bone marrow confined) 
metastasis and lesions located in the spine, while 18F-NaF 
PET/CT performed better with respect to osteosclerotic 
and rib lesions. Our results support the view that, when 
a functional method is needed, information derived by 
18F-FDG can correctly classify most breast cancer patients 
with suspected or known bone metastasis. However, the 
lesion-based analysis highlighted significant differences 
between the two imaging methods, which emphasize 
the different complementary information provided by 
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Figure 1  A 49-year-old breast cancer patient with bone relapse. A lytic lesion on the fifth lumbar vertebra was detected with computed tomography in absence 
of local pain (A). The lesion showed high uptake both at 18F-FDG PET/CT (B) and 18F-NaF PET/CT (C), thus confirming its malignant nature. No further 18F-FDG 
avid metastasis was highlighted (E). By contrast a focal area of high 18F-NaF uptake was evident in the anterior branch of the seventh rib on the left side (F). This 
area was indeed corresponding to a small sclerotic indeterminate lesion on the CT and was considered as a further site of disease (D). The patient started systemic 




Table 3  Sites and density characteristics showing different performance between 
2-deoxy-2-(18F)fluoro-D-glucose and 18F-sodium positron emission tomography/
computed tomography
n 18F-FDG 18F-NaF P
Density
   Osteosclerotic   89   0.005
      Sensitivity (%): 42.86 (15.82-74.95)   99.00 (64.57-99.00)
      Specificity (%): 97.00 (60.97-97.00)   48.15 (35.39-61.15)
   No lesion/bone marrow   29   0.002
      Sensitivity(%): 100.00 (60.97-100.00)   48.15 (30.74-66.01)
      Specificity(%): 100.00 (34.24-100.00)   100.00 (34.24-100.00)
Site
   Spine   81   0.002
      Sensitivity (%): 65.38 (51.80-76.85)   100.00 (93.12-100.00)
      Specificity (%): 98.00 (88.30-98.00) 13.45 (0.61-27.18)
   Ribs 118 0.04
      Sensitivity (%): 83.96 (75.81-89.74)   96.23 (90.70-98.52)
      Specificity (%): 78.37 (52.33-92.50)   78.57 (52.41-92.43)
18F-FDG: 2-deoxy-2-(18F)fluoro-D-glucose; 18F-NaF: 18F-sodium.
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the two tracers. In fact, these data fit with the different 
distribution mechanisms of the two tracers into bone 
metastases. More specifically, 18F-FDG accumulates into 
viable, metabolically-active tumor cells[34,35], while 18F-NaF 
is incorporated into bone crystals within the forming 
fluorapatite matrix, and thus tends to preferentially 
accumulate at sites of actively mineralizing bone[36,37]. 
Osseous metastases seed into the red bone marrow 
rather than the cortical bone, and this might explain the 
extremely high accuracy of 18F-FDG PET in detecting 
metastases confined in the bone marrow, especially at an 
earlier stage before the occurrence of bone reaction[38,39]. 
Accordingly, it has been suggested that 18F-FDG PET/CT 
can be assensitive as magnetic resonance imaging in 
this setting[40,41]. The relatively poor cellularity that may 
characterize sclerotic metastases, with relatively smaller 
volumes of tumor tissue in individual lesions, may 
influence the degree of 18F-FDG uptake given the small 
number of elements able to trap it[42].
These findings are thus coherent with the fact 
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Figure 2  Evidence of the complementary features of 2-deoxy-2-(18F)fluoro-D-glucose and 18F-sodium positron emission tomography/computed tomography 
in the pelvis of the same breast cancer patient. An 18F-NaF avid sclerotic lesion was detected in the right sacrum in absence of significant 18F-FDG uptake. By 
contrast high uptake of 18F-FDG was present in a small lytic lesion in the left iliac bone. Due to the absence of a significant local bone reaction, this small lesion did not 
show any uptake of 18F-NaF. Both lesions corresponded to metastatic sites of disease and disappeared after chemotherapy. 18F-FDG: 2-deoxy-2-(18F)fluoro-D-glucose; 
18F-NaF: 18F-sodium; PET/CT: Positron emission tomography/computed tomography.
A B
Figure 3  This area is likely to correspond to a bone marrow-confined metastasis not yet characterized by bone remodeling and thus falsely negative in 
both multidetector computed tomography and 18F-sodium positron emission tomography/computed tomography. No structural lesions or area of 18F-NaF 
uptake are evident in the vertebral column of this breast cancer patient (A); by contrast an area of high focal 18F-FDG uptake was present in the sixth dorsal vertebra (B). 
18F-NaF: 18F-sodium; 18F-FDG: 2-deoxy-2-(18F)fluoro-D-glucose.
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that 18F-FDG uptake is more specific for malignant 
lesions than bone metabolism tracers, while 18F-NaF is 
characterized by an extremely high sensitivity, rather 
than specificity, for both sclerotic and lytic lesions[43].
Surprisingly, both radiotracers showed high accuracy 
in the detection of lytic localizations, and no differences 
were highlighted between the accuracy of 18F-FDG or 
18F-NaF in the evaluation of this type of lesion. Previous 
studies compared the accuracy of 18F-FDG PET/CT and 
BS with respect to lytic lesions and found that 18F-FDG 
PET/CT is superior to BS in this setting[42,44]. Accordingly, 
the present findings support the concept that, although 
18F-NaF and BS highlight the same pathophysiological 
mechanisms (increased osteoblastic activity), the 
greater spatial resolution of PET accounts for the better 
diagnostic accuracy of 18F-NaF with respect to BS[24,43,45]. 
In fact, thanks to its better spatial resolution, this tracer 
is even capable of capturing the increased mineral 
metabolism related to the thin reactive border that may 
surround a lytic lesion. By contrast, this subtle reaction 
is generally too small to be detected by the limited 
spatial resolution of BS. However, it must be underlined 
that the extremely high sensitivity of 18F-NaF PET/CT in 
the detection of both lytic and sclerotic metastases is 
paralleled by a relatively low specificity[30]. 
This behavior might represent an important limi-
tation in the use of 18F-NaF PET and strongly advise 
in favor of the use of hybrid PET/CT imaging, thus 
increasing the specificity of 18F-NaF PET thanks to the 
CT-based characterization of bone remodeling (i.e., 
exclusion of clearly degenerative lesions)[31].
Significant differences between the two tracers were 
also found in the site-based analysis. In particular, the 
18F-FDG results were more accurate in detecting lesions 
located in the spine, while 18F-NaF provided a more 
accurate characterization of rib lesions. This could be 
related to the different structural modification induced by 
metastases as a function of their anatomical localization. 
Small lesions in the ribs can show an intense osteoblastic 
response, even in the presence of poor cellularity, and 
can therefore be easily identified by means of 18F-NaF[25]. 
By contrast, the highlighted superiority of 18F-FDG PET 
in the evaluation of spine lesions can be explained by 
the fact that many lesions located in the spine were, 
in this study, characterized by an absence of structural 
correlates in the co-registered CT. On the other hand, the 
age of our patient population (mean 60 years) may have 
also influenced the low accuracy of 18F-NaF for spine 
lesions. In fact, the presence of areas of non-specific 
18F-NaF uptake due to age-related degenerative changes 
may partially explain the relatively lower accuracy of 
18F-NaF in this site. This finding is in line with the notion 
that 18F-NaF is more accurate than BS, especially for 
evaluating vertebral localizations[46]. In fact, thanks 
to the greater resolution and fusion with CT, 18F-NaF 
can reduce the number off alse positive/indeterminate 
findings due to degenerative lesions. Although 18F-FDG 
can also be influenced by degenerative changes, the 
intensity and focality of these uptakes are lower with 
respect to bone metastasis; the glucose analogue is thus 
superior to both bone metabolism tracers in this setting.
Finally, when the specific influence of 18F-NaF was 
evaluated with respect to patient management, we 
found that adding 18F-NaF PET to patient work-up led to 
a change in management in 3 out of 45 patients, due 
to it revealing metastases undetected by 18F-FDG scan. 
These findings may underline that the extremely high 
sensitivity of 18F-NaF uptake can be useful in evaluating 
patients who are candidates for regional therapy (i.e., 
surgery or radiotherapy) with the aim of excluding 
patients with further occult metastases.
The present study has some limitations. It is a 
two center, retrospective study whose results may 
have been influenced by its patient population’s high 
pre-test probability of bone metastasis. Although 
the number of included patients was relatively small, 
it was comparable, or even higher, with respect to 
similar studies on the impact of different functional 
imaging techniques in breast cancer patients with bone 
metastasis[47,48]. Histological confirmation of metastases 
was not obtained in the majority of patients, for both 
practical and ethical reasons. A clinical, biochemical, 
and radiological follow-up of 12 mo was used as the 
standard of reference. Obviously, 12-mo follow-up 
findings might not be sufficient to exhaustively depict 
disease status. However, sclerotic and/or lytic bone 
lesions on CT are mostly accepted as metastases[49,50].
Additionally, in many other studies, clinical biopsy 
was performed only in a minority of patients and com-
parative imaging modalities were used as standard in 
order to assess metastatic bone involvement[51].
In conclusion, 18F-FDG PET/CT is a reliable imaging 
tool in the detection of bone metastasis in most cases, 
with a high diagnostic accuracy and superior specificity 
with respect to 18F-NaF PET/CT in the general population 
of breast cancer patients. However, the extremely high 
sensitivity of 18F-NaF PET/CT can exploit its diagnostic 
potential in specific clinical settings, such as small CT-
evident sclerotic lesions, possibly changing patient 
staging or management. Similarly, given the hereby 
proven complementary role of the two tracers, breast 
cancer patients could be candidates for 18F-NaF when, 
despite negative results in 18F-FDG and other imaging 
methods, they have suggestive clinical and biochemical 
sign of disease. Therefore 18F-NaF PET/CT emerges as 
a powerful “second-line” functional imaging tool, which 
may be of use in selected patients on the basis of their 
specific clinical history, in order to identify a priori in 




Early detection of bone metastases is of pivotal importance in breast cancer 
patients. To this purpose, besides conventional bone scintigraphy, positron 
emission tomography has become an established imaging modality, with 
better spatial resolution and superior image quality. Among positron emission 
tomography (PET) tracers, 2-deoxy-2-(18F)fluoro-D-glucose (18F-FDG) 
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represents the most widely used tracer in clinical routine, and can provide 
information about the presence or absence of disease in the skeleton, as well 
as in non-skeletal districts. However, characterization of bone metastases is 
also possible with 18F-sodium fluoride (18F-NaF). In this context, it has not yet 
been clearly investigated whether 18F-NaF PET/computed tomography (CT) can 
provide incremental information concerning breast cancer patients that have 
already been evaluated by means of FDG PET/CT.
Research frontiers
To date, controversial results have been reported about the accuracy of the two 
PET tracers in breast cancer patients,with some authors even proposing their 
combined use. This work aims to clarify whether, at least in specific conditions, 
these two tracers could be complementary in order to improve diagnostic 
accuracy in bone lesion characterization.
Innovations and breakthroughs
This work aims to compare the role of 18F-FDG and 18F-NaF PET/CT in re-
staging breast cancer patients with bone lesions through patient-, lesion 
density-, and site-based analyses. A more prompt and accurate characterization 
of bone alterations could lead to more accurate patient management.
Applications
Besides 18F-FDG, 18F-NaF PET/CT emerges as a powerful “second-line” 
functional imaging tool, which may be useful in selected patients on the basis of 
their specific clinical history.
Terminology
Glucose analogue 18F-FDG PET enables the detection of neoplastic lesions on 
the basis of their increased glucose metabolism directly reflecting tumor cell 
viability, thereby allowing forthe characterization of skeletal and extra-skeletal 
lesions. On the other hand, 18F-NaF reflects the increased regional blood flow 
and osteoblastic bone reaction being irreversibly incorporated into the bone 
matrix as fluorapatite.
Peer-review
An agreement on which is the best PET tracer in the characterization of bone 
lesions has not been yet been reached. In this study, the authors compared 
18F-FDG and 18F-NaF PET/CT accuracy in the restaging of breast cancer 
patients. They observed that, despite 18F-FDG PET/CT possibly being 
considered the most reliable tool in the general population of breast cancer 
patients, it can exploit its diagnostic potential in specific clinical settings. These 
results were interesting and provided important information concerning the 
most appropriate management of breast cancer patients with suspected bone 
metastases.
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